Search Results - "Cony‐Makhoul, Pascale"

Long‐term excess mortality and net survival among elderly diffuse large B‐cell lymphoma patients after front‐line R‐CHOP treatment by Belot, Aurélien, Camus, Vincent, Portugues, Cédric, Paget, Jérome, Chartier, Loic, Cony‐Makhoul, Pascale, Tilly, Hervé, Joubert, Clémentine

“…Summary In the era of immunochemotherapy, data on the long‐term prognosis of elderly patients diagnosed with a diffuse large B‐cell lymphoma (DLBCL) are…”
Get full text

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study by Rousselot, Philippe, Prost, Stéphane, Guilhot, Joelle, Roy, Lydia, Etienne, Gabriel, Legros, Laurence, Charbonnier, Aude, Coiteux, Valérie, Cony‐Makhoul, Pascale, Huguet, Francoise, Cayssials, Emilie, Cayuela, Jean‐Michel, Relouzat, Francis, Delord, Marc, Bruzzoni‐Giovanelli, Heriberto, Morisset, Laure, Mahon, François‐Xavier, Guilhot, François, Leboulch, Philippe

“…BACKGROUND We recently reported that peroxisome proliferator‐activated receptor γ agonists target chronic myeloid leukemia (CML) quiescent stem cells in vitro…”
Get full text

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group by Rea, Delphine, Ame, Shanti, Berger, Marc, Cayuela, Jean‐Michel, Charbonnier, Aude, Coiteux, Valérie, Cony‐Makhoul, Pascale, Dubruille, Viviane, Dulucq, Stéphanie, Etienne, Gabriel, Legros, Laurence, Nicolini, Franck, Roche‐Lestienne, Catherine, Escoffre‐Barbe, Martine, Gardembas, Martine, Guerci‐Bresler, Agnès, Johnson‐Ansah, Hyacinthe, Rigal‐Huguet, Françoise, Rousselot, Philippe, Mahon, François‐Xavier

“…BACKGROUND The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses…”
Get full text

Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients by Rohmer, Julien, Couteau‐Chardon, Amélie, Trichereau, Julie, Panel, Kewin, Gesquiere, Cyrielle, Ben Abdelali, Raouf, Bidet, Audrey, Bladé, Jean‐Sébastien, Cayuela, Jean‐Michel, Cony‐Makhoul, Pascale, Cottin, Vincent, Delabesse, Eric, Ebbo, Mikaël, Fain, Olivier, Flandrin, Pascale, Galicier, Lionel, Godon, Catherine, Grardel, Nathalie, Guffroy, Aurélien, Hamidou, Mohamed, Hunault, Mathilde, Lengline, Etienne, Lhomme, Faustine, Lhermitte, Ludovic, Machelart, Irène, Mauvieux, Laurent, Mohr, Catherine, Mozicconacci, Marie‐Joelle, Naguib, Dina, Nicolini, Franck E., Rey, Jerome, Rousselot, Philippe, Tavitian, Suzanne, Terriou, Louis, Lefèvre, Guillaume, Preudhomme, Claude, Kahn, Jean‐Emmanuel, Groh, Matthieu

“…FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia (F/P+ MN‐eo) is a rare disease: robust epidemiological data are lacking and reported issues are…”
Get full text

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome by Berger, Marc G., Pereira, Bruno, Rousselot, Philippe, Cony‐Makhoul, Pascale, Gardembas, Martine, Legros, Laurence, Escoffre‐Barbe, Martine, Nicolini, Franck‐Emmanuel, Saugues, Sandrine, Lambert, Céline, Réa, Delphine, Guerci‐Bresler, Agnès, Giraudier, Stéphane, Guilhot, Joëlle, Saussele, Susanne, Mahon, François‐Xavier

“…Summary The effectiveness of tyrosine kinase inhibitors (TKIs) has made it possible to consider treatment discontinuation in chronic myeloid leukaemia (CML)…”
Get full text

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study by Dulucq, Stéphanie, Rigal‐Huguet, Françoise, Nicolini, Franck E., Cony‐Makhoul, Pascale, Escoffre‐Barbe, Martine, Gardembas, Martine, Legros, Laurence, Rousselot, Philippe, Liu, Jixing, Rea, Delphine, De Mas, Véronique, Hayette, Sandrine, Raynaud, Sophie, Lacoste‐Roussillon, Caroline, Robbesyn, Fanny, Klein, Emilie, Morisset, Stéphane, Mahon, François‐Xavier, Etienne, Gabriel

“…Summary Molecular recurrence (MRec) occurs in about half of all patients with chronic myeloid leukaemia (CML) who discontinue tyrosine kinase inhibitors (TKI)…”
Get full text

Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real‐life study by Comont, Thibault, Meunier, Mathieu, Cherait, Amina, Santana, Clemence, Cluzeau, Thomas, Slama, Bohrane, Laribi, Kamel, Giraud, Jean‐Thomas, Dimicoli, Sophie, Berceanu, Ana, Le Clech, Lenaïg, Cony‐Makhoul, Pascale, Gruson, Berangere, Torregrosa, Jose, Sanhes, Laurence, Jachiet, Vincent, Azerad, Marie‐Agnes, Al Jijakli, Ahmad, Gyan, Emmanuel, Gaudin, Clement, Broner, Jonathan, Guerveno, Claire, Guillaume, Thierry, Ades, Pr Lionel, Beyne‐Rauzy, Odile, Fenaux, Pierre

“…Summary Despite a moderate prevalence in low‐risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), thrombocytopenia remains a risk…”
Get full text

Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM) by Jouzier, Claire, Cherait, Amina, Cony‐Makhoul, Pascale, Hamel, Jean‐François, Veloso, Melanie, Thepot, Sylvain, Cluzeau, Thomas, Stamatoullas, Aspasia, Garnier, Alice, Guerci‐Bresler, Agnès, Dimicoli‐Salazar, Sophie, Pica, Gian Matteo, Cheze, Stéphane, Santana, Clémence, Chermat, Fatiha, Fenaux, Pierre, Park, Sophie

“…Background MDS‐RS patients are characterized by chronic anemia and a low risk of Acute Myeloid Leukemia (AML) progression and they generally become Red Blood…”
Get full text

Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA‐PegIFN study) by Roy, Lydia, Chomel, Jean‐Claude, Guilhot, Joëlle, Guerci‐Bresler, Agnès, Escoffre‐Barbe, Martine, Giraudier, Stéphane, Charbonnier, Aude, Dubruille, Viviane, Huguet, Françoise, Johnson‐Ansah, Hyacinthe, Lenain, Pascal, Ame, Shanti, Etienne, Gabriel, Nicolini, Franck E., Rea, Delphine, Cony‐Makhoul, Pascale, Courby, Stéphane, Ianotto, Jean‐Christophe, Legros, Laurence, Machet, Antoine, Coiteux, Valérie, Hermet, Eric, Cayssials, Emilie, Bouchet, Stéphane, Mahon, Francois‐Xavier, Rousselot, Philippe, Guilhot, François

“…Summary Superior rates of deep molecular response (DMR) have been reported with the combination of tyrosine kinase inhibitors and pegylated‐interferon‐alpha…”
Get full text

Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add‐on study from the Groupe Francophone des Myelodysplasies by Prebet, Thomas, Delaunay, Jacques, Wattel, Eric, Braun, Thorsten, Cony‐Makhoul, Pascale, Dimicoli, Sophie, Wickenhauser, Stephan, Lejeune, Julie, Chevret, Sylvie, Chermat, Fatiha, Fenaux, Pierre, Vey, Norbert

Get full text

Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study by Dumontet, Charles, Demangel, Delphine, Galia, Perrine, Karlin, Lionel, Roche, Laurent, Fauvernier, Mathieu, Golfier, Camille, Laude, Marie‐Charlotte, Leleu, Xavier, Rodon, Philippe, Roussel, Murielle, Azaïs, Isabelle, Doyen, Chantal, Slama, Borhane, Manier, Salomon, Decaux, Olivier, Pertesi, Maroulio, Beaumont, Marie, Caillot, Denis, Boyle, Eileen M., Cliquennois, Manuel, Cony‐Makhoul, Pascale, Doncker, Anne‐Violaine, Dorvaux, Véronique, Petillon, Marie Odile, Fontan, Jean, Hivert, Bénédicte, Leduc, Isabelle, Leyronnas, Cécile, Macro, Margaret, Maigre, Michel, Mariette, Clara, Mineur, Philippe, Rigaudeau, Sophie, Royer, Bruno, Vincent, Laure, Mckay, James, Perrial, Emeline, Garderet, Laurent

“…Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively…”
Get full text

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells by Berger, Marc G., Lebecque, Benjamin, Tassin, Thomas, Dannus, Louis-Thomas, Berger, Juliette, Soucal, Mélanie, Guerci, Agnès, Cony-Makhoul, Pascale, Johnson, Hyacinthe, Etienne, Gabriel, Guyotat, Denis, Gagnieu, Marie-Claude, Pereira, Bruno, Saugues, Sandrine, Tournilhac, Olivier, Hermet, Eric, Bourgne, Céline

“…Accumulation in target cells is an essential pharmacokinetic step of targeted therapies. Tyrosine Kinase Inhibitors (TKI) against the BCR-ABL fusion protein in…”
Get full text

Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit? by Canet, Jim, Cony‐Makhoul, Pascale, Orazio, Sébastien, Cornet, Edouard, Troussard, Xavier, Maynadié, Marc, Étienne, Gabriel, Monnereau, Alain

“…Introduction Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new‐generation TKI (NG‐TKI) compared to…”
Get full text

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+CD15− cells in early chronic‐phase chronic myeloid leukemia by Maupetit‐Mehouas, Stéphanie, Court, Franck, Bourgne, Céline, Guerci‐Bresler, Agnès, Cony‐Makhoul, Pascale, Johnson, Hyacinthe, Etienne, Gabriel, Rousselot, Philippe, Guyotat, Denis, Janel, Alexandre, Hermet, Eric, Saugues, Sandrine, Berger, Juliette, Arnaud, Philippe, Berger, Marc G.

“…Despite the high efficiency of tyrosine kinase inhibitors (TKI), some patients with chronic myeloid leukemia (CML) will display residual disease that can…”
Get full text

Using healthcare claims data to analyze the prevalence of BCR‐ABL‐positive chronic myeloid leukemia in France: A nationwide population‐based study by Foulon, Stéphanie, Cony‐Makhoul, Pascale, Guerci‐Bresler, Agnès, Delord, Marc, Solary, Eric, Monnereau, Alain, Bonastre, Julia, Tubert‐Bitter, Pascale

“…Background Data on Chronic Myeloid Leukemia (CML) prevalence are scarce. Here we provide an estimation of the prevalence of CML in France for the year 2014…”
Get full text

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease by ROUSSELOT, Philippe, CHARBONNIER, Aude, ESCOFFRE-BARBE, Martine, GUERCI-BRESLER, Agnès, TULLIEZ, Michel, PROST, Stéphane, SPENTCHIAN, Marc, CAYUELA, Jean Michel, REIFFERS, Josy, CHOMEL, Jean Claude, TURHAN, Ali, GUILHOT, Joëlle, CONY-MAKHOUL, Pascale, GUILHOT, François, MAHON, François-Xavier, AGAPE, Philippe, NICOLINI, Franck E, VARET, Bruno, GARDEMBAS, Martine, ETIENNE, Gabriel, REA, Delphine, ROY, Lydia

“…More than half of patients with chronic-phase chronic myelogenous leukemia (CP-CML) in complete molecular response (CMR) experience molecular relapse after…”
Get full text

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients by Nicolini, Franck Emmanuel, Dulucq, Stéphanie, Boureau, Lisa, Cony-Makhoul, Pascale, Charbonnier, Aude, Escoffre-Barbe, Martine, Rigal-Huguet, Françoise, Coiteux, Valérie, Varet, Bruno, Dubruille, Viviane, Lenain, Pascal, Rousselot, Philippe, Rea, Delphine, Guerci-Bresler, Agnès, Legros, Laurence, Liu, Jixing, Gardembas, Martine, Ianotto, Jean-Christophe, Turlure, Pascal, Johnson-Ansah, Hyacinthe, Martiniuc, Juliana, Jardel, Henry, Joly, Bertrand, Zunic, Patricia, Henni, Tawfiq, Villemagne, Bruno, Berger, Marc G, Cayssials, Emilie, Guilhot, François, Larosa, Fabrice, Guilhot, Joëlle, Etienne, Gabriel, Mahon, François-Xavier

“…Tyrosine kinase inhibitor (TKI) discontinuation is an emerging goal in chronic myelogenous leukemia (CML) management and several studies have demonstrated the…”
Get full text

CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study by Durot, Eric, Roos-Weil, Damien, Chauchet, Adrien, Decroocq, Justine, Di Blasi, Roberta, Gastinne, Thomas, Bensader, Hedi, Cheminant, Morgane, Jacquet, Caroline, Guidez, Stephanie, Gros, François-Xavier, Bachy, Emmanuel, Cony-Makhoul, Pascale, Treon, Steven P, Delmer, Alain Jacques, Reshef, Ran, Le Gouill, Steven, Castillo, Jorge J., Houot, Roch

“…Introduction: Patients with histological transformation (HT) of Waldenström macroglobulinemia (WM) who relapse or are refractory (R/R) have a poor prognosis…”
Get full text

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry by Brisou, Gabriel, Cartron, Guillaume, Bachy, Emmanuel, Thieblemont, Catherine, Castilla-Llorente, Cristina, Le Bras, Fabien, Gros, François-Xavier, Loschi, Michael, Houot, Roch, Dulery, Remy, Jardin, Fabrice, Joris, Magalie, Sylvain, Choquet, Morschhauser, Franck, Guidez, Stephanie, Hermine, Olivier, Drieu La Rochelle, Laurianne, Carras, Sylvain, Guffroy, Blandine, Bories, Pierre, Casasnovas, Rene-Olivier, Abraham, Julie, Le Gouill, Steven, Cony-Makhoul, Pascale, Gat, Elodie, Tessoulin, Benoit

“…Background and Significance: Axicabtagene ciloleucel (axi-cel) has demonstrated superior efficacy as second-line therapy (2L) over standard of care…”
Get full text

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort by Saugues, Sandrine, Lambert, Céline, Daguenet, Elisabeth, Roth-Guepin, Gabrielle, Huguet, Françoise, Cony-Makhoul, Pascale, Ansah, Hyacinthe Johnson, Escoffre-Barbe, Martine, Turhan, Ali, Rousselot, Philippe, Tchirkov, Andreï, Hamroun, Dalil, Hermet, Eric, Pereira, Bruno, Berger, Marc G

“…In chronic myeloid leukemia, the identification of early molecular predictors of stable treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI)…”
Get full text